First in Human Single Ascending Dose Study of MOR107
Status:
Terminated
Trial end date:
2017-03-23
Target enrollment:
Participant gender:
Summary
This is the first in human study of MOR107. It is a 2 part, single centre, double-blind,
randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending
dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects
on a low sodium diet.